SCHEMBL17040320

SCHEMBL17040320

CC(NC(=O)OC(C)(C)C)c1cccc(F)c1F

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.43
CTSS P25774 2/20 0.43
TRPA1 O75762 1/20 0.41
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
HSD17B10 Q99714 3/20 0.39
MAPT P10636 2/20 0.39
MITF O75030 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482179 0.88 CTSK (0.47) CTSKCTSSTRPA1AAK1MAPT
SCHEMBL28937411 0.87 ATM (0.40) CTSKCTSSTRPA1HSD17B10MAPT
SCHEMBL28937402 0.87 ATM (0.40) CTSKCTSSTRPA1HSD17B10MAPT
SCHEMBL17041238 0.86 CTSK (0.40) CTSKCTSSTRPA1HSD17B10MAPT
SCHEMBL30006955 0.86 CTSK (0.38) CTSKCTSSTRPA1HSD17B10MAPT
SCHEMBL23081408 0.86 CES2 (0.38) CTSKCTSSTRPA1CES2CES1
SCHEMBL19234270 0.86 LMNA (0.42) CTSKCTSSTRPA1AAK1HSD17B10
SCHEMBL18854512 0.86 HTT (0.42) CTSKCTSSTRPA1AAK1MAPT
SCHEMBL16410288 0.86 LMNA (0.42) CTSKCTSSTRPA1AAK1HSD17B10
SCHEMBL29163981 0.86 CTSK (0.38) CTSKCTSSTRPA1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3107900-B1 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES SERVIER LAB (FR) 2017-11-15 EP disclosed
US-9809553-B2 Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-11-07 US disclosed
US-9809553-B2 Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-11-07 US disclosed
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-05-18 US disclosed
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-05-18 US disclosed
WO-2015124877-A1 DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES LES LABORATOIRES SERVIER (FR) 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137385-A1 ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MYLK, MYLK2, MYLK3 CTSK 2728/4885CTSS 3469/4885TRPA1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.